Facilitative effect of serotonin1a receptor agonists on cognition in patients with schizophrenia

Current Medicinal Chemistry

Volumn 20, Issue 3, 2013, Pages 357-362

  Sumiyoshi, T ^a   Higuchi, Y ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

5 HT1A; Cognitive function; Electrophysiology; Event related potentials; GABA; Glutamate; Prefrontal cortex; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; ARIPIPRAZOLE; BUSPIRONE; CLOZAPINE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; LURASIDONE; MELPERONE; MIRTAZAPINE; NORCLOZAPINE; OLANZAPINE; ONDANSETRON; PEROSPIRONE; PHENCYCLIDINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; TANDOSPIRONE; ZIPRASIDONE; SEROTONIN 1 AGONIST;

ARTICLE; ATTENTION; BRAIN ELECTROPHYSIOLOGY; COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG STRUCTURE; EVENT RELATED POTENTIAL; EXECUTIVE FUNCTION; HUMAN; LEARNING; LIMBIC SYSTEM; LOW RESOLUTION BRAIN ELECTROMAGNETIC TOMOGRAPHY; MENTAL PERFORMANCE; MOTOR PERFORMANCE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; UPREGULATION; VERBAL COMMUNICATION; VERBAL MEMORY; WORKING MEMORY; CHEMISTRY; DRUG EFFECTS; DRUG EFFECT; REVIEW;

COGNITION; HUMANS; SCHIZOPHRENIA; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84877954714     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320030006     Document Type: Article

References (41)

1. Harvey, P. D.; Keefe, R. S. Cognitive impairment in schizophrenia and implication of atypical neuroleptic treatment.CNS Spectr 1997, 2, 41-55. (Pubitemid 127791895)
2. Keefe, R. S.; Goldberg, T. E.; Harvey, P. D.; Gold, J. M.; Poe, M. P.; Coughenour, L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004, 68, 283-97. (Pubitemid 38526150)
3. Addington, J.; Addington, D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study Schizophr Res 2000, 44, 47-56. (Pubitemid 30365206)
4. Green, M. F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996, 153, 321-30. (Pubitemid 26074706)
5. Green, M. F.; Kern, R. S.; Braff, D. L.; Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr. Bull. 2000, 26, 119-36. (Pubitemid 30317696)
6. Harvey, P. D.; Ogasa, M.; Cucchiaro, J.; Loebel, A.; Keefe, R. S. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.Schizophr Res 2011, 127, 188-94.
7. Woodward, N. D.; Purdon, S. E.; Meltzer, H. Y.; Zald, D. H. A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8, 457-72. (Pubitemid 41002500)
8. Goldberg, T. E.; Goldman, R. S.; Burdick, K. E.; Malhotra, A. K.; Lencz, T.; Patel, R. C.; Woerner, M. G.; Schooler, N. R.; Kane, J. M.; Robinson, D. G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007, 64, 1115-22. (Pubitemid 47529336)
9. Newman-Tancredi, A.; Kleven, M. S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology 2011, 216, 451-73.
10. Ohno, Y.; Tatara, A.; Shimizu, S.; Sasa, M. Management of cognitive impairments in schizophrenia: the therapeutic role of 5-HT receptors. In: Sumiyoshi T, editor. Schizophrenia Research: Recent Advances. New York: Nova Science Publishers; 2012, 321-335.
11. Sumiyoshi, T. A possible dose-side effect relationship of antipsychotic drugs: Relevance to cognitive function in schizophrenia. Expert Rev Clin Pharmacol 2008, 1, 791-802.
12. Meltzer, H. Y.; Horiguchi, M.; Massey, B. W. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology 2011, 213, 289-305.
13. Sumiyoshi, T.; Uehara, T. Serotonin-1A receptors and cognitive enhancement in schizophrenia; Role for brain energy metabolism. In: Burne THJ, editor. Schizophrenia in the 21st Century. InTech; 2012 , 127-140.
14. Horiguchi, M.; Meltzer, H. Y. The role of 5-HT1A receptors in phencyclidine [PCP]-induced novel object recognition deficits in rats. Psychopharmacology 2012, 221, 205-15.
15. Llado-Pelfort, L.; Santana, N.; Ghisi, V.; Artigas, F.; Celada, P. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons.Cerebral Cortex 2012, 22, 1487-97.
16. Newman-Tancredi, A.; Albert, P. R. Gene polymorphism at serotonin 5-HT1A receptors: moving towards personalized medicine for psychosis and mood deficits? In: Sumiyoshi T, editor. Schizophrenia Research: Recent Advances. New York: Nova Science Publishers; 2012, 337-358.
17. Depoortere, R.; Auclair, A. L.; Bardin, L.; Colpaert, F. C.; Vacher, B.; Newman-Tancredi, A. F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol 2010, 20, 641-54.
18. Horiguchi, M.; Huang, M.; Meltzer, H. Y. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exper Ther 2011, 338, 605-14.
19. Horiguchi, M.; Huang, M.; Meltzer, H. Y. Interaction of mGlu/ agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology. 2011, 217, 13-24.
20. Meltzer, H. Y.; Massey, B. W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011, 11, 59-67.
21. Stenberg, J. H.; Terevnikov, V.; Joffe, M.; Tiihonen, J.; Tchoukhine, E.; Burkin, M.; Joffe, G. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Inter J Neuropsychopharmacol 2010, 13, 433-41.
22. Akhondzadeh, S.; Mohammadi, N.; Noroozian, M.; Karamghadiri, N.; Ghoreishi, A.; Jamshidi, A. H.; Forghani, S. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophrenia Res 2009, 107, 206-12.
23. Sumiyoshi, T.; Matsui, M.; Nohara, S.; Yamashita, I.; Kurachi, M.; Sumiyoshi, C.; Jayathilake, K.; Meltzer, H. Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001, 158, 1722-5. (Pubitemid 32923670)
24. Sumiyoshi, T.; Matsui, M.; Yamashita, I.; Nohara, S.; Kurachi, M.; Uehara, T.; Sumiyoshi, S.; Sumiyoshi, C.; Meltzer, H. Y. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiat 2001, 49, 861-8. (Pubitemid 32436390)
25. Sumiyoshi, T.; Park, S.; Jayathilake, K.; Roy, A.; Ertugrul, A.; Meltzer, H. Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2007, 95, 158-68. (Pubitemid 47313647)
26. Bortolozzi, A.; Masana, M.; Diaz-Mataix, L.; Cortes, R.; Scorza, M. C.; Gingrich, J. A.; Toth, M.; Artigas, F. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. Int J Neuropsychopharmacol 2010, 13, 1299-314.
27. Diaz-Mataix, L.; Scorza, M. C.; Bortolozzi, A.; Toth, M.; Celada, P.; Artigas, F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005, 25, 10831-43. (Pubitemid 41692613)
28. Ichikawa, J.; Ishii, H.; Bonaccorso, S.; Fowler, W. L.; O'Laughlin, I. A.; Meltzer, H. Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001, 76, 1521-31. (Pubitemid 32198256)
29. Llado-Pelfort, L.; Assie, M. B.; Newman-Tancredi, A.; Artigas, F.; Celada, P. Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. Br J Pharmacol 2010, 160, 1929-40.
30. Higuchi, Y.; Sumiyoshi, T.; Kawasaki, Y.; Ito, T.; Seo, T.; Suzuki, M. Effect of tandospirone on mismatch negativity and cognitive performance in schizophrenia: a case report. J Clin Psychopharmacol 2010, 30, 732-4.
31. Sumiyoshi, T.; Higuchi, Y.; Itoh, T.; Kawasaki, Y. Electrophysiological imaging evaluation of schizophrenia and treatment response. In: Risner MS, editor. Handbook of Schizophrenia Spectrum Disorders,: Springer; 2011.,135-148.
32. Pascual-Marqui, R. D. Review of methods for solving the EEG inverse problem. Int J Bioelectromagnetism 1999, 1, 75-86.
33. Sumiyoshi, T.; Higuchi, Y.; Itoh, T.; Matsui, M.; Arai, H.; Suzuki, M.; Kurachi, M.; Sumiyoshi, C.; Kawasaki, Y. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a threedimensional analysis with sloreta. Psychiatry Res 2009, 172, 180-3.
34. Araki, T.; Yamasue, H.; Sumiyoshi, T.; Kuwabara, H.; Suga, M.; Iwanami, A.; Kato, N.; Kasai, K. Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30, 204-8. (Pubitemid 43288059)
35. Sumiyoshi, T.; Higuchi, Y.; Matsui, M.; Arai, H.; Takamiya, C.; Meltzer, H. Y.; Kurachi, M. Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31, 965-7. (Pubitemid 46660309)
36. Matsui, M.; Sumiyoshi, T.; Yuuki, H.; Kato, K.; Kurachi, M. Impairment of event schema in patients with schizophrenia: examination of script for shopping at supermarket. Psychiatry Res 2006, 143, 179-87. (Pubitemid 44301515)
37. Hashimoto, T.; Nishino, N.; Nakai, H.; Tanaka, C. Increase in serotonin 5HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991, 48, 355-63.
38. Sumiyoshi, T.; Stockmeier, C. A.; Overholser, J. C.; Dilley, G. E.; Meltzer, H. Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 1996, 708, 209-14.
39. Tauscher, J.; Kapur, S.; Verhoeff, P. L. G.; Hussey, D. F.; Daskalakis, Z. J.; Tauscher-Wisniewski, S.; Wilson, A. A.; Houle, S.; Kasper, S.; Zipurski, R. B. Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychaitry 2002, 59, 514-20. (Pubitemid 34602933)
40. Sumiyoshi, T. Serotonin 1A receptors in the action of antipsychotic drugs. J Psychopharmacol. 2012, 26, 1283-4.
41. Kaneda, Y.; Sumiyoshi, T.; Keefe, R.; Ishimoto, Y.; Numata, S.; Ohmori, T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci 2007, 61, 602-9. (Pubitemid 350233482)